Morningside Pharmaceuticals Limited Pharmaceutical Import Profile — United Kingdom (DGFT 2022–2026)

Name: Morningside Pharmaceuticals Limited Pharmaceutical Import Records from India — 2 Products, $7.7M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Morningside Pharmaceuticals Limited — Pharmaceutical Importer Profile (2026) | 2 Products, $7.7M Trade | TransData Nexus

Morningside Pharmaceuticals Limited

Pharmaceutical Importer · United Kingdom · Diabetes & Endocrine Focus · $7.7M Total Trade · DGFT Verified

Morningside Pharmaceuticals Limited is a pharmaceutical importer based in United Kingdom with a total trade value of $7.7M across 2 products in 2 therapeutic categories. Based on 155 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Morningside Pharmaceuticals Limited sources from 10 verified Indian suppliers, with Usv Private Limited accounting for 81.1% of imports.

Morningside Pharmaceuticals Limited — Import Portfolio & Supplier Network

Morningside Pharmaceuticals Limited import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Morningside Pharmaceuticals Limited?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Usv Private Limited	$16.7M	512	81.1%
Apex Laboratories Private Limited	$1.3M	59	6.3%
Alembic Pharmaceuticals Limited

What Formulations Does Morningside Pharmaceuticals Limited Import?

Formulation	Value	Ships
Sukkarto sr 500 MG tabs 14s gb (4x14s)	$353.7K	8
Vensir xl cap 150 MG 28 s (2x14 s) uk	$315.6K	7
Sukkarto sr (metformin hydrochloride	$282.4K	8
Sukkarto sr (metformin hydrochloride)	$260.4K	8
Metformin hcl pr tabs 500 MG 2x14's gb	$254.3K	7
Sukkarto sr (metformin hydrochloride	$250.0K	5
Sukkarto sr (metformin hydrochloride)	$250.0K	5
Sukkarto sr metformin hydrochloride	$244.4K	7
Drugs and pharmaceuticals harmless	$200.2K	6
Sukkarto sr 1000 MG tabs14sgb(4x14s) (mfg. date feb-2025 exp. date jan-2028)	$200.0K	4
Sukkarto sr 500 MG tabs 14s gb 4x14s	$172.6K	5
Sukkarto sr 500 MG tabs 14s gb (4x14s)	$167.4K	4
Acitretin 25MG capsules BP 6x10's gb	$157.4K	4
Delofine xl 5 MG pr TAB 2x14's gb	$153.5K	4
Sukkarto sr 500MG tabs 14 s gb 4x14 s batch no 18039019 39021 mfg apr 25 exp mar28 18039023 39024 mfg may 25 exp apr	$150.0K	3

Morningside Pharmaceuticals Limited imports 461 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Metformin	Diabetes & Endocrine	$5.6M	113	1.2%	13
2	Gabapentin	CNS & Psychiatric	$2.1M	42	0.2%	7

Morningside Pharmaceuticals Limited imports 2 pharmaceutical products across 2 categories into United Kingdom totaling $7.7M.

Morningside Pharmaceuticals Limited — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Morningside Pharmaceuticals Limited, established in 1991, is a UK-based manufacturer, wholesaler, distributor, and exporter of both generic and branded medicines, as well as healthcare products. Headquartered in Loughborough, England, the company has been a significant player in the pharmaceutical sector for over three decades. In October 2022, Morningside was acquired by Aspire Pharma Limited, a move aimed at enhancing their combined growth and international expansion efforts.

The company offers a diverse portfolio covering various therapeutic areas, including cardiology, endocrinology, gynecology, immunology, neurology, oncology, and tuberculosis. Morningside's products are distributed to NHS hospitals and pharmacies across the UK, with global exports reaching over 120 countries. Their clientele includes international aid agencies, charities, and NGOs such as UNICEF, the World Health Organization (WHO), the Red Cross, and Médecins Sans Frontières (MSF).

2Distribution Network

Morningside Pharmaceuticals Limited operates from two primary locations:

Loughborough, England: 5 Pavilion Way, Castle Business Park, Loughborough, LE11 5GW.
Northampton, England: Nene House, 4 Rushmills, Northampton, NN4 7YB. (craft.co)

The company has a robust logistics network, ensuring timely distribution of licensed medicines to NHS hospitals and pharmacies throughout the UK. Additionally, Morningside exports to over 120 countries, supplying medicines to global aid agencies, charities, and NGOs.

3Industry Role

Morningside Pharmaceuticals Limited functions as a manufacturer, wholesaler, distributor, and exporter of generic and branded medicines and healthcare products. In the United Kingdom, the company supplies licensed medicines to NHS hospitals and pharmacies, while globally, it exports to over 120 countries, including supplying medicines to international aid agencies, charities, and NGOs.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Morningside Pharmaceuticals Limited

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Morningside Pharmaceuticals Limited's sourcing strategy from India reveals a high concentration on a few suppliers. The company has imported finished pharmaceutical formulations from 10 unique Indian suppliers, with the top five accounting for 96.5% of the total import value. USV Private Limited leads with $16.7 million (81.1% share), followed by Apex Laboratories Private Limited ($1.3 million, 6.3%), Alembic Pharmaceuticals Limited ($1.2 million, 5.8%), Titan Laboratories Private Limited ($475,000, 2.3%), and Ind Swift Limited ($296,000, 1.4%).

This concentration suggests a strategic choice to maintain strong, stable relationships with key suppliers, potentially ensuring consistent product quality and supply reliability. However, such dependency also poses risks, including supply chain disruptions if any of these primary suppliers face operational challenges.

2Supply Chain Resilience

Morningside Pharmaceuticals Limited's supply chain from India appears to be resilient, given the company's reliance on a select group of suppliers. The diversity of formulations imported—461 unique products—indicates a broad product range, which can mitigate risks associated with dependency on specific suppliers. However, the heavy reliance on USV Private Limited (81.1% share) suggests that any disruptions with this supplier could significantly impact Morningside's operations.

Importing Pharmaceuticals into United Kingdom — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for United Kingdom

1Regulatory Authority & Framework

In the United Kingdom, the Medicines and Healthcare products Regulatory Agency (MHRA) is the primary regulatory body overseeing pharmaceutical imports. The MHRA ensures that medicines and medical devices meet appropriate standards of safety, quality, and efficacy. Key legislation governing pharmaceutical imports includes the Human Medicines Regulations 2012, which transposes EU directives into UK law, and the Medicines Act 1968.

The marketing authorization pathway for Indian generics involves obtaining a UK Marketing Authorization (MA) from the MHRA. This process requires submission of comprehensive data demonstrating the product's quality, safety, and efficacy. Once authorized, the product can be imported and marketed in the UK.

2Import Licensing & GMP

Import licensing requirements in the UK are stringent. Importers must hold a Wholesale Dealer's License issued by the MHRA, which authorizes the importation and distribution of medicinal products. Additionally, Good Manufacturing Practice (GMP) certification is mandatory. The UK recognizes GMP certificates from the European Union (EU GMP), World Health Organization (WHO GMP), and the Pharmaceutical Inspection Co-operation Scheme (PIC/S).

Indian exporters seeking to supply Morningside Pharmaceuticals Limited must ensure their manufacturing facilities are GMP-compliant and hold the necessary certifications recognized by the MHRA.

Morningside Pharmaceuticals Limited — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Morningside Pharmaceuticals Limited's focus on importing products in the Diabetes & Endocrine (72.6%) and CNS & Psychiatric (27.4%) therapeutic categories aligns with global health priorities and addresses significant patient needs. The high import value of Metformin ($5.6 million) and Gabapentin ($2.1 million) indicates strong market demand for these medications in the UK. This strategic focus allows Morningside to cater to prevalent health conditions, ensuring a steady demand for their products.

2Sourcing Profile

Morningside Pharmaceuticals Limited's sourcing strategy emphasizes importing finished pharmaceutical formulations from India, particularly in the therapeutic areas of Diabetes & Endocrine and CNS & Psychiatric. This approach leverages India's manufacturing capabilities and cost advantages. The company's reliance on a select group of suppliers, notably USV Private Limited, suggests a preference for established partnerships that can consistently meet quality and supply requirements.

3Market Positioning

Based on its product mix, Morningside Pharmaceuticals Limited serves multiple segments of the UK pharmaceutical market. The company's focus on generic and branded medicines positions it to supply retail pharmacies, hospitals, and government tenders. Additionally, its export activities to international aid agencies and NGOs indicate a broader market reach, encompassing global humanitarian efforts.

Seller's Guide — How to Become a Supplier to Morningside Pharmaceuticals Limited

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to engage with Morningside Pharmaceuticals Limited. The company's diverse product portfolio and reliance on a select group of suppliers suggest potential gaps that new entrants could fill. Suppliers offering a range of formulations in the therapeutic areas of Diabetes & Endocrine and CNS & Psychiatric may find opportunities to become alternative suppliers, thereby reducing Morningside's supply chain risks.

2Requirements & Qualifications

Indian exporters aiming to supply Morningside Pharmaceuticals Limited and the UK market must ensure their manufacturing facilities are compliant with GMP standards recognized by the MHRA, such as EU GMP, WHO GMP, or PIC/S certifications. Additionally, they must obtain the necessary import licenses and adhere to UK labeling and serialization requirements. Maintaining high-quality standards and ensuring regulatory compliance are crucial for successful market entry.

3How to Approach

Frequently Asked Questions — Morningside Pharmaceuticals Limited

What products does Morningside Pharmaceuticals Limited import from India?

Morningside Pharmaceuticals Limited imports 2 pharmaceutical products across 2 categories. Top imports: Metformin ($5.6M), Gabapentin ($2.1M).

Who supplies pharmaceuticals to Morningside Pharmaceuticals Limited from India?

Morningside Pharmaceuticals Limited sources from 10 verified Indian suppliers. The primary supplier is Usv Private Limited (81.1% of imports, $16.7M).

What is Morningside Pharmaceuticals Limited's total pharmaceutical import value?

Morningside Pharmaceuticals Limited's total pharmaceutical import value from India is $7.7M, based on 155 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Morningside Pharmaceuticals Limited focus on?

Morningside Pharmaceuticals Limited imports across 2 categories. The largest: Diabetes & Endocrine (72.6%), CNS & Psychiatric (27.4%).

Get Full Morningside Pharmaceuticals Limited Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.